Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice

World Journal of Gastroenterology

Volumn 14, Issue 17, 2008, Pages 2757-2762

  Ageloni, Stefania ^a   Leboffe, Cinzia ^a   Parente, Antonella ^a   Venditti, Mario ^a   Giordano, Alessandra ^a   Merli, Manuela ^a   Riggio, Oliviero ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antibiotic resistant pathogens; Ascitic polymorphonuclear count; Cefotaxime; Cirrhosis; Spontaneous bacterial peritonitis

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASCITES FLUID; BACTERIAL PERITONITIS; BACTERIUM CULTURE; CELL COUNT; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HUMAN; LIVER CIRRHOSIS; MALE; POLYMORPHONUCLEAR CELL; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; MICROBIOLOGY; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PERITONITIS; VALIDATION STUDY;

AGED; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; BACTERIAL INFECTIONS; CEFOTAXIME; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEUTROPHILS; PERITONITIS; PRACTICE GUIDELINES AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 48349086631     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2757     Document Type: Article

References (37)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358
2. Pinzello G, Simonetti RG, Craxi A, Di Piazza S, Spano C, Pagliaro L. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983; 3: 545-549
3. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis, and prognosis. Scand J Gastroenterol 1987; 22: 295-300
4. Llach J, Rimola A, Navasa M, Gines P, Salmeron JM, Gines A, Arroyo V, Rodes J. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724-727
5. Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: an update. Mayo Clin Proc 1995; 70: 365-370
6. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005; 42 Suppl: S85-S92
7. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31
8. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: variations on a theme. Medicine (Baltimore) 1971; 50: 161-197
9. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis - in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001; 96 1232-1236
10. Llovet JM, Planas R, Morillas R, Quer JC, Cabre E, Boix J, Humbert P, Guilera M, bomenech E, Bertran X. Short-term prognosis of cirrhotics; with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993; 88: 388-392
11. Toledo C, Salmeron JM, Rimola A, Navasa. M, Arroyo V, Llach J, Gines A, Gines P, Rodes J. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251-257
12. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142-153
13. Hoefs JC. Diagnostic paracentesis. A potent clinical tool. Gastroenterology 1990; 98: 230-236
14. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, Rodes J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-148
15. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003; 9: 531-537
16. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ. Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int 2005; 25: 57-61
17. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-1070
18. Park YH, Lee HC, Song HG, Jung S, Ryu SH, Shin JW, Chung YH, Lee YS, Suh DJ. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18: 927-933
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
20. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
21. Angeloni S, Nicolini G, Merh M, Nicolao F, Pinto G, Aronne T, Attih AF, Riggio O. Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol 2003; 98: 1844-1848
22. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95: 1351-1355
23. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, Albillos A, Jimenez W, Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218
24. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139-142
25. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-1212
26. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-1661
27. Folio A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodes J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501
28. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginos P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409
29. Salerno F, Gerbes A, Ginos P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318
30. Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, Rodes J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457-462
31. Rimola A, Salmeron JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, Guarner C, Planas R, Sola R, Vargas V. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21: 674-679
32. Navasa M, Folio A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forne M, Planas R, Banares R, Castells L, Jimenez De Anta MT, Arroyo V, Rodes J. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111: 1011-1017
33. Ricart E, Soriano G, Novella MT, Ortiz J, Sabat M, Kolle L, Sola-Vera J, Minana J, Dedou JM, Gomez C, Barrio IL, Guarner C. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000; 32: 596-602
34. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100: 1737-1742
35. Chen TA, Lo GH, Lai KH, Lin WJ. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World J Gastroenterol 2005; 11: 6823-6827
36. Carattoli A, Garcia-Fernandez A, Varesi P, Fortini D, Gerardi S, Penni A, Mancini C, Giordano A. Molecular epidemiology of Escherichia coh producing extended-spectrurn beta-lactamases isolated in Rome, Italy. J Clin Microbiol 2008; 46: 103-108
37. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton Dj. Health care - associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797